Antitumor effect of novel gallium compounds and efficacy of nanoparticle-mediated gallium delivery in lung cancer

Journal of Biomedical Nanotechnology

Volumn 8, Issue 1, 2012, Pages 161-171

  Wehrung, Daniel ^a   Oyewumi, Moses O ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Biocompatibility; Cytotoxicity; Gallium acetylacetonate; Gallium hexanedione; Human lung adenocarcinoma cells; Nanoparticles

Indexed keywords

A549 CELLS; ACETYLACETONATES; ANTI-TUMORS; ANTITUMOR EFFECT; CANCER THERAPY; CELL VIABILITY; CETYL ALCOHOL; HUMAN LUNG; HUMAN LUNG ADENOCARCINOMA CELLS; INCUBATION TIME; LOW CONCENTRATIONS; LUNG CANCER; MATRIX MATERIALS; REACTIVE OXYGEN SPECIES; TRANSFERRIN RECEPTORS; TUMOR ACCUMULATION; TUMOR UPTAKE; UPTAKE MECHANISM;

BINARY MIXTURES; BIOCOMPATIBILITY; CYTOTOXICITY; GALLIUM COMPOUNDS; NANOPARTICLES; ONCOLOGY; RESPIRATORY SYSTEM; TUMORS;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; GALLIUM; GALLIUM ACETYLACETONATE; GALLIUM HEXANEDIONE; NANOPARTICLE; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG STABILITY; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG ADENOCARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR STABILITY; MORPHOLOGY; PARTICLE SIZE;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; COORDINATION COMPLEXES; DRUG CARRIERS; DRUG STABILITY; ENDOCYTOSIS; GALLIUM; HEMOLYSIS; HUMANS; LUNG NEOPLASMS; MATERIALS TESTING; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOPARTICLES; PARTICLE SIZE; PLATELET AGGREGATION; REACTIVE OXYGEN SPECIES; TRANSFERRIN;

EID: 84859160978     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1361     Document Type: Article

References (34)

1. S. Wang, R. J. Lee, C. J. Mathias, M. A. Green, and P. S. Low, Synthesis, purification, and tumor cell uptake of 67-Ga-deferioxaminefolate, a potential radiopharmaceutical for tumor imaging. Bioconjugate Chem. 7, 55 (1996).
2. N. Viola-Villegas, A. Vortherms, and R. P. Doyle, Targeting gallium to cancer cells through folate receptors. Drug Target Insights 3, 13 (2008).
3. C. R. Chitambar and D. P. Purpi, A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk. Res. 34, 950 (2010).
4. S. Gomez-Ruiz, B. Gallego, M. Kaluderovic, H. Kommera, E. Hey- Hawkins, R. Paschke, and G. N. Kaluderovic, Novel gallium (III) complexes containing phthaloyl derivatives of neutral amino acids with apoptotic activity in cancer cells. J. Org. Met. Chem. 694, 2191 (2009).
5. C. R. Chitambar, Medical applications and toxicities of gallium compounds. Int. J. Environ. Res. Public Health 7, 2337 (2010).
6. L. R. Bernstein, Mechanisms of therapeutic activity of gallium. Pharmacol. Rev. 50, 665 (1998).
7. P. Collery, B. Keppler, C. Madoulet, and B. Desoize, Gallium in cancer treatment. Crit. Rev Oncol. Hematol. 42, 283 (2002).
8. D. R. Richardson, D. S. Kalinowski, S. Lau, P. J. Jansson, and D. B. Lovejoy, Cancer cell iron metabolism and the development of potent iron chelators as anti-tumor agents. Biochim. Biophys. Acta 1790, 702 (2009).
9. D. W. Hedley, E. H. Tripp, and G. J. Mann, Effect of gallium on DNA synthesis by human T -cell lymphoblasts. Cancer Res. 48, 3014 (1988).
10. M. A. Jakupec and B. K. Keppler, Gallium and other main group of metal compounds as antitumor agents. Met. Ions. Biol. Syst. 42, 425 (2004).
11. L. R. Bernstein, T. Tanner, C. Godfrey, and B. Noll, Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Metal-Based Drugs 7, 33 (2000).
12. G. M. Knorr and C. R. Chitambar, Gallium-pyridoxal isonicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate. Anticancer Res. 18, 1733 (1998).
13. M. R. Kaluderovic, S. Gomez-Ruiz, B. Gallego, E. Hey-Hawkins, R. Paschke, and G. N. Kaluderovic, Anticancer activity of dinuclear gallium (III) carboxylate complexes. Eur. J. Med. Chem. 45, 519 (2010).
14. M. S. Chua, L. R. Bernstein, R. Li, and S. K. So, Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 26, 1739 (2006).
15. M. O. Oyewumi and R. J. Mumper, Gadolinium-loaded nanoparticles engineered from microemulsion templates. Drug Dev. Ind. Pharm. 28, 317 (2002).
16. M. O. Oyewumi and, R. J. Mumper, Engineering tumor-targeted gadolinium nanoparticles for potential application in neutron capture therapy. Bioconjugate Chem. 13, 1328 (2002).
17. M. O. Oyewumi and R. J. Mumper, Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharm. 251, 85 (2003).
18. R. J. Mumper and M. Jay, The formation and stability of lanthanide complexes and their encapsulation into polymeric microspheres. J. Phys. Chem. 96, 8626 (1992).
19. M. O. Oyewumi, R. A. Yokel, M. Jay, T. Coakley, and R. J. Mumper, Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Rel. 95, 613 (2004).
20. J. M. Koziara, J. J. Oh, W. S. Akers, S. P. Ferraris, and R. J. Mumper, Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22, 1821 (2005).
21. N. Yanasarn, B.R. Sloat, and Z. Cui, Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int. J. Pharm. 379, 174 (2009).
22. L. Yang, Y. Yatomi, Y. Satoh, and Y. Ozaki, Inhibitory effects of berapost on platelet aggregation: Comparative study utilizing two methods of aggregometry. Throm. Res. 94, 25 (1999).
23. M. Buyukavci, O. Ozdemir, S. Buck, M. Stout, Y. Ravindranath, and S. Savasan, Melatonin cytotoxicity in human leukemia cells: Relation with pro-oxidant effect Fundam. Clin. Pharmacol. 20, 73 (2006).
24. T. Dederichs, M. Möller, and O. Weichold, Temperature-dependent colloidal stability of hydrophobic nanoparticles caused by surfactant adsorption/desorption and depletion flocculation. Langmuir 25:18, 10501 (2009).
25. L. Wu, J. Zhang, and W. Watanabe, Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63, 456 (2011).
26. M. O. Oyewumi, A. Kumar, and Z. Cui, Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines. 9, 1095 (2010).
27. V. B. Patravale, A. A. Date, and R. M. Kulkarni, Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 56, 827 (2004).
28. C. R. Chitambar, D. P. Purpi, J. Woodliff, M. Yang, and J. P. Wereley, Development of gallium compounds for treatment of lymphoma: Gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents cell resistance to gallium nitrate. J. Pharmacol. Exp. Ther. 322, 1228 (2007).
29. C. Ballot, J. Kluza, A. Martoriati, U. Nyaman, P. Formstecher, B. Joseph, C. Bailly, and P. Marchetti, Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamelarin D. Mol. Cancer Ther. 8, 3307 (2009).
30. H. Luo, L. Juan, and X. Chen, Antitumor effect of N-succinyl-chitosan nanoparticles on K562 cells. Biomed. Pharmacother. 8, 521 (2010).
31. C. R. Chitambar, Apoptotic mechanisms of gallium nitrate: Basic and clinical investigations. Oncology 13, 39 (2004).
32. J. S. Rasey, N. J. Nelson, and S. M. Larson, Tumor cell toxicity of stable gallium nitrate: enhancement of transferrin and protection by iron. Eur. J. Cancer Clin. Oncol. 18, 661 (1982).
33. C. R. Chitambar and J. P. Wereley, Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake. J. Biol. Chem. 272, 12151 (1997).
34. N. P. Davies, Y. S. Rahmanto, C. R. Chitambar, and D. R. Richardson, Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: Identification of novel intermediates. J. Pharmacol. Exp. Ther. 317, 153 (2005).